Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1975;83(1):31-55.
doi: 10.1007/BF00284400.

[ct-Mode of Action in the Teratogenic Experiment]

[Article in German]

[ct-Mode of Action in the Teratogenic Experiment]

[Article in German]
P Hafen et al. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1975.

Abstract

The doses of 10 and 20 mg/kg N-methyl-N-nitrosourea which were teratogenetically effective after a single dose were distributed over 12,24, 48, and 96 hrs during the embryonic developmental phase of the rat. It turned out that the effects were enormously increased when both doses were given in ten single doses during 12 hrs. The number of fetuses that had died down during gestation was increased considerably, the surviving fetuses bore, without exception, the marks of extreme malformations, as, for example, big haemorrhagic cysts instead of the mandible and the tongue. The distribution of the doses over 24 hrs showed, as far as quantity is concerned, comparable teratogenic effects, which, however, during the time of treatment varied in quality according to the variation of the critical sensitivity of the developmental phase. The distribution over even longer periods of time gradually weakened the effect. There were also some other symptoms that became manifest. So it can be said that N-methyl-N-nitrosourea is according to its teratogenic effects also a typical ct-poison (Druckrey) with the maximum of cumulation after distributing the dose over 12 hrs of the gestation.

PubMed Disclaimer

Similar articles

References

    1. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1965 Nov 18;252(2):196-204 - PubMed
    1. Arzneimittelforschung. 1971 Jan;21(1):13-5 - PubMed
    1. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1975;83(1):31-55 - PubMed
    1. Arzneimittelforschung. 1969 Jul;19(7):1091-3 - PubMed
    1. Arzneimittelforschung. 1970 Mar;20(3):418-9 - PubMed

Publication types